RxDoctor Payments Data

Alaa Gabi, MD

Interventional Cardiology · Stockton, CANPI 1114281524

Payments from drug & device makers

$28,887in general payments, 2019–2025

Across 584 payments — averaging $49.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Boston Scientific$4K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • AstraZeneca$889
  • Amgen$887
  • plus $6K from 33 others

What the payments were for

  • Travel & lodging$14,96052%
  • Food & beverage$13,75948%
  • Education$1681%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,887 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$454,362
Medicare patients
1,337
Services billed
4,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$145,797
XareltoRivaroxaban107$101,788
EntrestoSacubitril/Valsartan44$55,033
JardianceEmpagliflozin58$53,078
Repatha SureclickEvolocumab29$23,999
MultaqDronedarone Hcl12$14,238
Repatha SyringeEvolocumab13$9,348
Metoprolol Succinate265$2,450
Atorvastatin Calcium272$1,862
Losartan Potassium235$1,456
ClopidogrelClopidogrel Bisulfate193$1,347
Rosuvastatin Calcium65$1,048
Potassium Chloride46$835
Carvedilol98$758
Amlodipine Besylate252$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$215$145,797125 claims
Johnson & JohnsonXarelto$497$101,788107 claims
NovartisEntresto$476$55,03344 claims
Boehringer IngelheimJardiance$90$53,07858 claims
Sanofi-aventis U.S. LLCMultaq$188$14,23812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →